3 completed. 1 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow AA Secord: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Pembrolizumab - Gynecologic Neoplasms, Epithelial Ovarian Cancer | Early Phase 1 | Completed | AA Secord | 39 | 2016-06-01 | 2024-02-21 |
| BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer BIBF 1120 - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | AA Secord | 32 | 2013-02-01 | 2018-10-16 |
| PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer Dasatinib, Paclitaxel, and Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 1 | Completed | AA Secord | 11 | 2007-08-01 | 2012-12-28 |
Fallopian Tube Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Ovarian Neoplasms (2) · Endometrial Neoplasms (1) · Genital Neoplasms, Female (1)
Carboplatin (1) · Dasatinib (1) · Paclitaxel (1) · nintedanib (1) · pembrolizumab (1)
United States (3)